Ghrelin, the hunger hormone peptide, partially protected male mice from cisplatin chemotherapy-induced testicular damage and weight loss through its specific receptor GHSR-1a.
GHSR-1a dependent protectionGhrelin protected testicles from cisplatin damage in normal mice but not in GHSR knockout mice, confirming the effect is specifically mediated through the ghrelin receptor — a finding that validates the therapeutic target.
What the researchers found
The hunger hormone peptide ghrelin partially protected against cisplatin-induced testicular damage and cachexia (muscle wasting) in male mice. When given alongside cisplatin chemotherapy, ghrelin significantly increased body, testicular, and epididymal weights while reducing testicular cell death. The widespread damage to sperm-producing tissue (seminiferous epithelium) caused by cisplatin was less severe with ghrelin co-treatment. Critically, these protective effects were absent in mice lacking the ghrelin receptor (GHSR-1a), confirming the effects are specifically mediated through this receptor and not off-target.
Why it matters
Cisplatin is one of the most effective and widely used chemotherapy drugs, but high cumulative doses can cause permanent infertility in male cancer patients through testicular damage. Currently, sperm banking before treatment is the main fertility preservation option. If ghrelin or a stable GHSR agonist could protect testicular tissue during chemotherapy, it would represent a fundamentally different approach — preserving natural fertility rather than relying on cryopreservation. This is especially important for young cancer patients facing a lifetime of potential infertility.
The numbers in context
2 treatment cycles (9 and 18 days) · GHSR-1a dependent protection · Body, testicular, and epididymal weights all improved · Testicular cell death reduced
How the study worked
Adult male C57Bl/6 mice received intraperitoneal injections of vehicle, ghrelin, cisplatin alone, or cisplatin plus ghrelin in cycles of 9 or 18 days. Body weight was measured daily. At study end, testicular and epididymal weights, sperm density and motility, testicular histology, and testicular cell death were analyzed. The role of the ghrelin receptor was confirmed using GHSR knockout mice.
Who was studied
Adult male C57Bl/6 mice and GHSR knockout mice treated with cisplatin with or without ghrelin
What this study cannot tell us
This is a mouse study — cisplatin dosing, ghrelin pharmacokinetics, and testicular biology differ between mice and humans. The study doesn't address whether ghrelin protection might interfere with cisplatin's anticancer efficacy. Specific sperm count and motility data are mentioned but not quantified in the abstract. Long-term reproductive outcomes (actual fertility/offspring) were not assessed. The optimal timing, dose, and duration of ghrelin co-administration for clinical translation remain unknown.
How to read the evidence
This is a well-controlled animal study using both wild-type and receptor knockout mice to establish mechanism. The use of knockout controls significantly strengthens the mechanistic conclusions. However, it remains preclinical with no human data, and important questions about cancer efficacy interference are unanswered.
When this study was published
Published in 2015, this study remains relevant as a foundational preclinical finding. Ghrelin and GHSR agonists continue to be explored for various protective roles in chemotherapy, though clinical translation for gonadal protection has been slow.
The bigger picture
Fertility preservation is increasingly recognized as an essential component of cancer care, especially for adolescent and young adult patients. Current options are limited — mainly sperm banking before treatment. The concept of pharmacological gonadal protection during chemotherapy (giving a drug alongside chemo to shield reproductive tissue) has been explored with various agents, but none have reached clinical practice. Ghrelin's dual ability to protect both testicular tissue and body weight (combating cachexia) makes it a particularly attractive candidate for this purpose.
Questions still open
- Does ghrelin protection of the testicles interfere with cisplatin's ability to kill cancer cells?
- Would stable GHSR agonists (synthetic ghrelin-like drugs) provide better or more sustained testicular protection than natural ghrelin?
- Can these findings be translated to human clinical trials in male cancer patients receiving cisplatin-based chemotherapy?
Common questions
What is ghrelin and why might it protect the testicles?
Could this help prevent infertility in men undergoing chemotherapy?
Read the original research
Ghrelin partially protects against cisplatin-induced male murine gonadal toxicity in a GHSR-1a-dependent manner.
Biology of reproduction, 92(3), 76
Citation
Whirledge, Shannon D; Garcia, Jose M; Smith, Roy G; Lamb, Dolores J. (2015). Ghrelin partially protects against cisplatin-induced male murine gonadal toxicity in a GHSR-1a-dependent manner.. Biology of reproduction, 92(3), 76. https://doi.org/10.1095/biolreprod.114.123570